Meanwhile, although we could show that LATS2 depletion functionally confers regorafenib resistance in the HCC cells, it does not necessarily mean that HCC cells acquire chemoresistance by inactivating LATS2 in the clinical setting. Here, LATS2 is linked to hepatocellular carcinoma.